<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area"^^ . "Sir,\n\nIn their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered.\n\nFirstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors’ experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al...."^^ . "2020-12" . . "36" . "3" . . "Human Reproduction"^^ . . . "02681161" . . . . . . . . . . "Ana Teresa"^^ . "Marcos Rodríguez"^^ . "Ana Teresa Marcos Rodríguez"^^ . . "José Manuel"^^ . "Navarro-Pando"^^ . "José Manuel Navarro-Pando"^^ . . . . . "HTML Summary of #510 \n\nLetter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area\n\n" . "text/html" . . . "Biomedicine"@en . "Biomedicina"@es . .